

## Daily Program Schedule

### Wednesday September 25, 2024

8:00-9:00	<b>OPENING CEREMONY</b> <b>P D V</b>	
8:00-8:05	Welcome	
8:05-8:30	Pioneers in Myeloma	
8:30-9:00	President's Address	Philippe Moreau
9:00-9:30	<b>KEYNOTE</b> <b>P D V</b>	Anant Madabhushi
9:30-10:00	<b>BREAK</b>	
10:00-11:30	<b>PRECURSOR DISEASE</b> <b>P D V</b>	
	<i>Chair: Sagar Lonial, Co-chair: Maria-Victoria Mateos</i>	
10:00-10:10	Approaches to Risk Stratification in High Risk Myeloma	Irene Ghobrial
10:10-10:20	What we have learnt from iSTOPMM?	Sigurdur Kristinsson
10:20-10:30	Co-evolution of Immune Response in Multiple Myeloma: Implications for Immune Prevention	Madhav Dhodapkar
10:30-10:40	Current approach for the management of SMM	Vincent Rajkumar
10:40-11:00	Future Directions and Challenges	Maria-Victoria Mateos
11:00-11:30	Round Table discussion	Session faculty + Elena Zamagni
11:30-12:30	<b>ABSTRACT SESSION 1</b> <b>P D</b>	
	<i>Co-chairs: Natalie Callander and Sergio Giralt</i>	
11:30-12:30	<b>ABSTRACT SESSION 2</b> <b>P D</b>	
	<i>Co-chairs: Niccolo Bolli and Michel Delforge</i>	
12:30-13:30	<b>LUNCH AND POSTERS</b>	
13:30-15:00	<b>INDUSTRY SYMPOSIUM</b> <b>P D V</b>	

15:00-16:30	<b>NEWLY DIAGNOSED</b> P D V	
	<i>Chair: Jesus San Miguel, Co-chair: Philippe Moreau</i>	
15:00-15:10	Induction therapy in Transplant Eligible Patients	Francesca Gay
15:10-15:20	What is the best consolidation/maintenance?	Ajay Nooka
15:20-15:30	Is there any genomic and immune signatures predicting outcome in NDMM?	Nizar Bahlis
15:30-15:40	Management of NDMM in low income countries	Dorotea Fantl
15:40-15:50	Transplant Ineligible Patients	Salomon Manier
15:50 - 16:05	Future Directions and Challenges	Philippe Moreau
16:05 - 16:30	Round Table discussion	Session faculty + Masahiro Abe

16:30-17:00 **BREAK**

17:00 - 18:00	<b>MRD IS AN END POINT: OUR SUCCESS STORY</b> P D V	
	<i>Co-chairs: Brian Durie and Jean-Luc Harousseau</i>	
	<i>Speakers: Jesus San Miguel, Shaji Kumar, Nikhil Munshi</i>	
	Round Table discussion	Session faculty + Ola Landgren

18:00 - 19:00	<b>POSTER SESSION</b> P	
	<i>Discussants: Rafat Abonour, Diana Cirstea, P. Joy Ho, Andrew Yee</i>	

## Thursday, September 26, 2024

7:00-8:00	<b>MEET THE EXPERT</b> P	
	Role of Transplant	Morie Gertz and Heinz Ludwig
	Frailty-adapted therapy	Gordon Cook and Alessandra Larocca
	Extramedullary disease/PCI	Laura Rosiñol and Yael Cohen
	How to manage 2L+ in the near future?	Rafael Fonesca and Leo Rasche

8:00-9:00 **INDUSTRY SYMPOSIUM** P D V

9:00-10:30	<b>HIGH RISK DISEASE</b> <b>P D V</b> <i>Chair: Simon Harrison, Co-chair: Faith Davies</i>	
9:00-9:10	New classification for identifying HR Myeloma based on cytogenetic abnormalities	Jill Corre
9:10-9:20	Other factors for identification of high risk beyond cytogenetic	Wee Joo Chng
9:20-9:30	How to characterize and manage the functional high risk Myeloma	Martin Kaiser
9:30-9:40	Management of HR Disease--Can change to Clinical Trials in HR disease	Katja Weisel
9:40-10:00	Future Directions and Challenges	Faith Davies
10:00-10:30	Round Table discussion	Session faculty + Angelo Maiolino
10:30-11:00	<b>BREAK</b>	
11:00-12:30	<b>INDUSTRY SYMPOSIUM</b> <b>P D V</b>	
12:30-13:30	<b>LUNCH AND POSTERS</b>	
13:30-14:30	<b>WALDENSTROM AWARD</b> <b>P D V</b>	
14:30-15:30	<b>IMS/EHA SYMPOSIUM: CURRENT AND FUTURE GUIDELINES</b> <b>P D V</b> <i>Co-chairs: Philippe Moreau and Pieter Sonneveld</i>	
14:30-14:45	American Perspective	Luciano Costa
14:45-15:00	European Perspective	Paula Rodriguez-Otero
15:00-15:30	Round Table discussion	Thomas Martin and Michel Delforge
15:30-16:00	<b>BREAK</b>	
16:00-17:30	<b>RELAPSED: TREATMENTS OUTSIDE OF IMMUNOTHERAPY</b> <b>P D V</b> <i>Chair: Vania Hungria, Co-chair: Keith Stewart</i>	
16:00-16:10	Genomic Evolution at the Time of Relapse	Mehmet Samur
16:10-16:20	Treating Relapsed MM outside of use of TC redirected Therapies	Amrita Krishnan
16:20-16:30	Targeted therapies in RR MM: BCL2, BRAF, MEK, MMSET	Marc Raab
16:30-16:40	Treatment of RRMM in resource restricted regions	Hang Quach
16:40-17:00	Future directions and challenges	Keith Stewart
17:00-17:30	Round Table discussion	Sesison faculty + Pankaj Malhotra
17:30-18:30	<b>ABSTRACT SESSION 3</b> <b>P D</b> <i>Co-chair: Charlotte Pawlyn and Andrzej Jakubowiak</i>	

---

17:30-18:30 **ABSTRACT SESSION 4** **P D**  
*Co-chair: Nicola Giuliani and Steven Treon*

## Friday, September 27, 2024

7:00-8:00 **MEET THE EXPERT** **P**

Use of Bispecifics and CAR T cells in South America	Jesus Berdeja and Natalia Schütz
Supportive care in the setting of TCR	Surbhi Sidana and Hira Mian
Myeloma defining events: renal failure and bone disease	Ramon Garcia Sanz and Evangelos Terpos
Waldenstrom's and other plasma cell disorders:	Jorge Castillo and Prashant Kapoor

---

8:00-9:00 **INDUSTRY SYMPOSIUM** **P D V**

---

9:00-10:00 **ABSTRACT SESSION 5** **P D**  
*Co-chairs: Meral Beksac and Michael O'Dwyer*

---

9:00-10:00 **ABSTRACT SESSION 6** **P D**  
*Co-chairs: Manoj Bhasin and Francesco Maura*

---

10:00-10:30 **BREAK**

---

10:30-12:00 **IMMUNOTHERAPY** **P D V**  
*Chair: Noopur Raje, Co-chair: Nikhil Munshi*

10:30-10:40	BCMA/GPRC5D/FcRH5 – CARs/BsAbs – Clinical Update	Ajai Chari
10:40-10:50	Choice of TCR and How to sequence?	Paula Rodriguez-Otero
10:50-11:00	Mechanisms of resistance to CAR-T and BsAbs	Paola Neri
11:00-11:10	Strategies to overcome the T-cell exhaustion	Hermann Einsele
11:10-11:30	Future Directions and Challenges	Nikhil Munshi
11:30-12:00	Round Table discussion	Session faculty + Niels van de Donk

---

12:00-13:00 **LUNCH AND POSTERS**

---

13:00-14:00 **RINEY SESSION** **P D V**  
*Co-chairs: Kenneth Anderson and Nikhil Munshi*

---

14:00-16:00 **PLENARY SESSION** **P D V**  
*Co-chairs: Leif Bergsagel and Kwee Yong*

---

16:00-16:30	<b>BREAK</b>	
16:30-17:30	<b>MOVING THE PATHS TO APPROVAL: REGULATORY CONSIDERATIONS</b> <b>P D V</b> <i>Co-chairs: Thierry Facon and Nikhil Munshi</i>	Nicole Gormley and Bindu Kanapuru
	US	
	Europe	Edward Laane and Francesco Pignatti
	Discussion	
17:30-18:30	<b>ABSTRACT SESSION 7</b> <b>P D</b> <i>Co-chairs: Tanya Wildes and Javier de la Rubia</i>	
17:30-18:30	<b>ABSTRACT SESSION 8</b> <b>P D</b> <i>Co-chairs: Dharminder Chauhan and Andrew Spencer</i>	
18:30 - 19:30	<b>POSTER SESSION</b> <b>P</b> <i>Discussants: Noa Biran, Ben Derman, Efsthios Kastritis, Adam Sperling, Lugui Qiu</i>	

## Saturday, September 28, 2024

7:00-8:00	<b>MEET THE EXPERT</b> <b>P</b>	
	Career in Basic Science	Mala Shanmugam and Marta Chesi
	Career in Translational Research	Jens Lohr and Lawrence Boise
	Career as a Clinical Trialist	Aurore Perrot and Karthik Ramasamy
	Women in Science	Mariateresa Fulcinitti and Claire Edwards
8:00-9:00	<b>INDUSTRY SYMPOSIUM</b> <b>P D V</b>	
9:00-10:00	<b>EMERGING TARGETS IN DRUG THERAPIES</b> <b>P D V</b> <i>Co-chairs: Sundar Jagannath and Robert Orloski</i>	
10:00-11:00	<b>ABSTRACT SESSION 9</b> <b>P D</b> <i>Chair: Al Garfall and Enrique Ocio</i>	
10:00-11:00	<b>ABSTRACT SESSION 10</b> <b>P D</b> <i>Co-chairs: Raphael Szalat and Gareth Morgan</i>	
11:00-11:15	<b>BREAK</b>	

11:15-12:15	<b>ABSTRACT SESSION 11</b> <b>P D</b> <i>Co-chairs: Samir Parekh and Brian Walker</i>	
11:15-12:15	<b>ABSTRACT SESSION 12</b> <b>P D</b> <i>Co-chairs: Constantine Mitsiades and Damian Green</i>	
12:15-13:45	<b>NOVEL BIOMARKERS - PERSONALIZING THERAPY IN MYELOMA</b> <b>P D V</b> <i>Chair: Kenneth Anderson, Co-chair: Shaji Kumar</i>	
12:15-12:25	MRD as a biomarker for treatment decisions	Saad Usmani
12:25-12:35	Novel biomarkers in Myeloma: CTCs and cfDNA	Bruno Paiva
12:35-12:45	Genetic and epigenetic markers for drug selection	Suzanne Trudel
12:45-12:55	Biomarker strategy for minimizing toxicity	Ashley Rosko
12:55-13:15	Future Directions and Challenges	Shaji Kumar
13:15-13:45	Round Table discussion	Session faculty + Noemi Puig
13:45-14:00	<b>CLOSING CEREMONIES</b> <b>P D V</b>	

**The IMS gratefully acknowledges the following organizations for their sponsorship of the 21st IMS Annual Meeting:**

**TITANIUM LEVEL**



**PLATINUM LEVEL**



**GOLD LEVEL**

